LIXT
HEALTHCARELixte Biotechnology Holdings Inc
$4.40-0.09 (-1.90%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving LIXT Today?
No stock-specific AI insight has been generated for LIXT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.64$6.26
$4.40
Fundamentals
Market Cap$51M
P/E Ratio—
EPS$-1.26
Dividend Yield—
Dividend / Share—
ROE-1.0%
Profit Margin—
Debt / Equity—
Trading
Volume100K
Avg Volume (10D)—
Shares Outstanding11.6M
LIXT News
20 articles- LIXTE Biotechnology Holdings (LIXT) Unlocking New Potential in Precision Cancer TreatmentYahoo Finance·Apr 27, 2026
- LIXTE Biotechnology Holdings (LIXT) Positions LB-100 as Novel Approach in Cancer Treatment LandscapeYahoo Finance·Apr 20, 2026
- Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are BuiltYahoo Finance·Apr 17, 2026
- LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO ConferenceYahoo Finance·Apr 13, 2026
- Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care ConferenceYahoo Finance·Apr 13, 2026
- Lixte Biotech Holdings (LIXT) Advances Precision Oncology Strategy With LB-100, Expands Clinical and Strategic PartnershipsYahoo Finance·Apr 10, 2026
- LIXTE Biotechnology Holdings (LIXT) Files 2025 Form 10-K, Highlights Transformational YearYahoo Finance·Apr 2, 2026
- LIXTE Biotechnology (LIXT) Has the World's Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment OutcomesYahoo Finance·Apr 1, 2026
- LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative YearYahoo Finance·Mar 31, 2026
- LIXTE Biotechnology (LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical TrialsYahoo Finance·Mar 31, 2026
- Lixte Biotech (LIXT) Advances Precision Oncology With LB-100, Strengthens Position Through Liora Technologies PartnershipYahoo Finance·Mar 27, 2026
- Landmark Proton Therapy Data Changes the Conversation; LIXTE Biotechnology (LIXT) Saw It ComingYahoo Finance·Mar 25, 2026
- LIXTE Biotechnology (LIXT) Advances PP2A Inhibition Strategy in Evolving Oncology LandscapeYahoo Finance·Mar 23, 2026
- LIXTE Biotechnology Holdings (LIXT) Adds Innovative LiGHT Therapy to PipelineYahoo Finance·Mar 10, 2026
- LIXTE Biotechnology (LIXT) Advances Lead Compound in Tumor Immunogenicity ResearchYahoo Finance·Mar 9, 2026
- LIXTE Biotechnology (LIXT) Appoints Sidney Braun as CEO of Liora Technologies Europe SubsidiaryYahoo Finance·Feb 18, 2026
- LIXTE Biotechnology Appoints Sidney Braun as CEO of its Liora Technologies Europe Ltd. SubsidiaryYahoo Finance·Feb 18, 2026
- LIXTE Biotechnology (LIXT) Bringing First-in-Class Approach to Chemo and ImmunotherapyYahoo Finance·Feb 12, 2026
- LIXTE Biotechnology (LIXT) Aligns Liora and LiGHT System With LB-100 to Push Frontier of Cancer TreatmentYahoo Finance·Feb 10, 2026
- LIXTE Biotechnology (LIXT) Positions LB-100 to Expand Effectiveness of Standard Cancer TreatmentYahoo Finance·Feb 9, 2026
All 20 articles loaded
Price Data
Open$3.42
Previous Close$4.49
Day High$3.44
Day Low$3.34
52 Week High$6.26
52 Week Low$0.64
52-Week Range
$0.64$6.26
$4.40
Fundamentals
Market Cap$51M
P/E Ratio—
EPS$-1.26
Dividend Yield—
Dividend / Share—
ROE-1.0%
Profit Margin—
Debt / Equity—
Trading
Volume100K
Avg Volume (10D)—
Shares Outstanding11.6M
About Lixte Biotechnology Holdings Inc
Lixte Biotechnology Holdings, Inc. is a drug discovery company that uses biomarker technology to identify enzyme targets related to serious common diseases and designs novel compounds to attack those targets. The company is headquartered in East Setauket, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—